van den Bergh, J. P.
Geusens, P.
Appelman-Dijkstra, N. M.
van den Broek, H. J. G.
Elders, P. J. M.
de Klerk, G.
van Oostwaard, M.
Willems, H. C.
Zillikens, M. C.
Lems, W. F.
Article History
Received: 10 November 2023
Accepted: 26 January 2024
First Online: 2 April 2024
Declarations
:
: JvdB: lecture fees from Amgen, UCB; PG: lecture fees/advisory boards Sanzoz, MSD, Galapagos, Fresenius, Celltrion, Amgen; NMA-D: lecture fees from Amgen, UCB. Research funding Takeda, Kyowa Kirin, UCB; GdK: lecture fees from Amgen; HW: lecture fees from Amgen, UCB; WFL: lecture fees/advisory boards from Amgen, UCB, Pfizer, Galapagos; HvdB, PE, MO, MCZ, GdK no conflict of interest.